

Generic Name: Sulbactam Sodium/Cefoperazone Sodium
Trade Name: SULPERAZON
CDS Effective Date: October 14, 2022
Supersedes: March 28, 2019
Approved by BPOM: November 15, 2023

**PT Pfizer Indonesia
Local Product Document**

**Generic Name: Sulbactam Sodium/Cefoperazone Sodium
Trade Name: SULPERAZON
CDS Effective Date: October 14, 2022
Supersedes: March 28, 2019**

DESCRIPTION

Sulbactam sodium is a derivative of the basic penicillin nucleus. It is an irreversible beta-lactamase inhibitor for parenteral use only. Chemically it is sodium penicillinate sulfone. It contains 92 mg sodium (4 mEq) per gram. Sulbactam is an off-white crystalline powder which is highly soluble in water. The molecular weight is 255.22.

Cefoperazone sodium is a semisynthetic broad-spectrum cephalosporin antibiotic for parenteral use only. It contains 34 mg sodium (1.5 mEq) per gram. Cefoperazone is a white crystalline powder which is freely soluble in water. The molecular weight is 667.65.

SULPERAZON brand of sulbactam sodium/cefoperazone sodium combination is available as a dry powder for reconstitution in a 1:1 in terms of free SBT/CPZ. Vials of the 1:1 product contain the equivalent of 500 mg + 500 mg of sulbactam and cefoperazone, respectively.

PHARMACOLOGICAL PROPERTIES

Pharmacokinetics Properties

Approximately 84% of the sulbactam dose and 25% of the cefoperazone dose administered with SULPERAZON is excreted by the kidney. Most of the remaining dose of cefoperazone is excreted in the bile. After SULPERAZON administration the mean half-life for sulbactam is about 1 hour while that for cefoperazone is 1.7 hours. Serum concentrations have been shown to be proportional to the dose administered. These values are consistent with previously published values for the agents when given alone.

* SULPERAZON is a trademark of Pfizer Inc.

Mean peak sulbactam and cefoperazone concentrations after the administration of single dose 2 grams of SULPERAZON (1 g sulbactam, 1 g of cefoperazone) intravenously over 5 minutes were 130.2 and 236.8 mcg/ml respectively. This reflects the larger volume of distribution for sulbactam ($V_d = 18.0-27.6$ L) compared to cefoperazone ($V_d = 10.2-11.3$ L).

Generic Name: Sulbactam Sodium/Cefoperazone Sodium
Trade Name: SULPERAZON
CDS Effective Date: October 14, 2022
Supersedes: March 28, 2019
Approved by BPOM: November 15, 2023

Both sulbactam and cefoperazone distribute well into a variety of tissues and fluids including bile, gall bladder, skin, appendix, fallopian tubes, ovary, uterus, and others.

There is no evidence of any pharmacokinetic drug interaction between sulbactam and cefoperazone when administered together in the form of sulbactam/cefoperazone.

After multiple dosing no significant changes in the pharmacokinetics of either component of SULPERAZON have been reported and no accumulation has been observed when administered every 8 to 12 hours.

Use in Hepatic Dysfunction

See section SPECIAL WARNINGS AND PRECAUTIONS FOR USE.

Use in Renal Dysfunction

In patients with different degrees of renal function administered SULPERAZON, the total body clearance of sulbactam was highly correlated with estimated creatinine clearance. Patients who are functionally anephric showed a significantly longer half-life of sulbactam (mean 6.9 and 9.7 hours in separate studies). Haemodialysis significantly altered the half-life, total body clearance, and volume of distribution of sulbactam. No significant differences have been observed in the pharmacokinetics of cefoperazone in renal failure patients.

Use in Elderly

The pharmacokinetics of SULPERAZON have been studied in elderly individuals with renal insufficiency and compromised hepatic function. Both sulbactam and cefoperazone exhibited longer half-life, lower clearance, and larger volumes of distribution when compared to data from normal volunteers. The pharmacokinetics of sulbactam correlated well with the degree of renal dysfunction while for cefoperazone there was a good correlation with the degree of hepatic dysfunction.

Use in Children

Studies conducted in pediatrics have shown no significant changes in the pharmacokinetics of the components of SULPERAZON compared to adult values. The mean half-life in children has ranged from 0.91 to 1.42 hours for sulbactam and from 1.44 to 1.88 hours for cefoperazone.

Pre-clinical Safety Data

Usage in Pediatrics

Generic Name: Sulbactam Sodium/Cefoperazone Sodium
Trade Name: SULPERAZON
CDS Effective Date: October 14, 2022
Supersedes: March 28, 2019
Approved by BPOM: November 15, 2023

Cefoperazone had adverse effects on the testes of pre-pubertal rats at all doses tested. Subcutaneous administration of 1,000 mg/kg per day (approximately 16 times the average adult human dose) resulted in reduced testicular weight, arrested spermatogenesis, reduced germinal cell population and vacuolation of Sertoli cell cytoplasm. The severity of lesions was dose dependent in the 100 to 1,000 mg/kg/day range; the low dose caused a minor decrease in spermatocytes. This effect has not been observed in adult rats. Histologically the lesions were reversible at all but the highest dosage levels. However, these studies did not evaluate subsequent development of reproductive function in the rats. The relationship of these findings to humans is unknown.

When SULPERAZON (1:1) was given S.C. to neonatal rats for 1 month reduced testicular weights and immature tubules were seen in groups given 300 + 300 mg/kg/day. Because there is a great individual variation in the degree of testicular maturation in rat pups and because immature testes were found in controls any relation to study drug is uncertain. No such findings were seen in infant dogs at doses over 10 times the average adult dose.

Pharmacodynamic Properties

The anti-bacterial component of SULPERAZON is cefoperazone, a third generation cephalosporin, which acts against sensitive organisms during the stage of active multiplication by inhibiting biosynthesis of cell wall mucopeptide. Sulbactam does not possess any useful antibacterial activity, except against *Neisseriaceae* and *Acinetobacter*. However, biochemical studies with cell-free bacterial systems have shown it to be an irreversible inhibitor of most important beta-lactamases produced by beta-lactam antibiotic-resistant organisms.

The potential for sulbactam's preventing the destruction of penicillins and cephalosporins by resistant organisms was confirmed in whole-organism studies using resistant strains in which sulbactam exhibited marked synergy with penicillins and cephalosporins. As sulbactam also binds with some penicillin binding proteins, sensitive strains are also often rendered more susceptible to SULPERAZON than to cefoperazone alone.

The combination of sulbactam and cefoperazone is active against all organisms sensitive to cefoperazone. In addition it demonstrates synergistic activity (up to four-fold reduction in minimum inhibitory concentrations for the combination versus those for each component) in a variety of organisms, most markedly the following:

Haemophilus influenzae
Bacteroides species
Staphylococcus species
Acinetobacter calcoaceticus
Enterobacter aerogenes
Escherichia coli
Proteus mirabilis
Klebsiella pneumoniae

Generic Name: Sulbactam Sodium/Cefoperazone Sodium
Trade Name: SULPERAZON
CDS Effective Date: October 14, 2022
Supersedes: March 28, 2019
Approved by BPOM: November 15, 2023

Morganella morganii
Citrobacter freundii
Enterobacter cloacae
Citrobacter diversus

SULPERAZON is active *in vitro* against a wide variety of clinically significant organisms:

Gram-positive Organisms:

Staphylococcus aureus, penicillinase and non-penicillinase-producing strains
Staphylococcus epidermidis
Streptococcus pneumoniae (formerly *Diplococcus pneumoniae*)
Streptococcus pyogenes (Group A beta-hemolytic streptococci)
Streptococcus agalactiae (Group B beta-hemolytic streptococci)
Most other strains of beta-hemolytic streptococci
Many strains of *Streptococcus faecalis* (enterococcus)

Gram-negative Organisms:

Escherichia coli
Klebsiella species
Enterobacter species
Citrobacter species
Haemophilus influenzae
Proteus mirabilis
Proteus vulgaris
Morganella morganii (formerly *Proteus morganii*)
Providencia rettgeri (formerly *Proteus rettgeri*)
Providencia species
Serratia species (including *S. marcescens*)
Salmonella and *Shigella* species
Pseudomonas aeruginosa and some other *Pseudomonas* species
Acinetobacter calcoaceticus
Neisseria gonorrhoeae
Neisseria meningitidis
Bordetella pertussis
Yersinia enterocolitica

Anaerobic Organisms:

Gram-negative bacilli (including *Bacteroides fragilis*, other *Bacteroides* species, and *Fusobacterium* species)

Generic Name: Sulbactam Sodium/Cefoperazone Sodium
 Trade Name: SULPERAZON
 CDS Effective Date: October 14, 2022
 Supersedes: March 28, 2019
 Approved by BPOM: November 15, 2023

Gram-positive and gram-negative cocci (including *Peptococcus*, *Peptostreptococcus* and *Veillonella* species)

Gram-positive bacilli (including *Clostridium*, *Eubacterium* and *Lactobacillus* species)

The following susceptibility ranges have been established for SULPERAZON:

	Minimal inhibitory concentration (MIC), (mcg/ml-expressed as cefoperazone concentration)
Susceptible	≤ 16
Intermediate	17-63
Resistant	≥ 64

	Susceptibility Disc Zone Size, mm (Kirby-Bauer)
Susceptible	≥ 21
Intermediate	16-20
Resistant	≤ 15

For MIC determinations, serial dilutions of SULPERAZON in a 1:1 or 1:2 sulbactam/cefoperazone ratio may be used with a broth or agar dilution method. Use of a susceptibility test disc containing 30 mcg of sulbactam and 75 mcg of cefoperazone is recommended. A report from the laboratory of "susceptible" indicates that the infecting organism is likely to respond to SULPERAZON therapy, and a report of "Resistant" indicates that the organism is not likely to respond. A report of "Intermediate" suggests that the organism would be susceptible to SULPERAZON if a higher dosage is used or if the infection is confined to tissues or fluids where high antibiotic levels are attained.

The following quality control limits are recommended for 30 mcg/75 mcg sulbactam/cefoperazone susceptibility discs.

CONTROL STRAIN	ZONE SIZE mm
----------------	--------------

<i>Acinetobacter</i> spp., ATCC 43498	26 - 32
--	---------

Generic Name: Sulbactam Sodium/Cefoperazone Sodium
Trade Name: SULPERAZON
CDS Effective Date: October 14, 2022
Supersedes: March 28, 2019
Approved by BPOM: November 15, 2023

<i>Pseudomonas aeruginosa</i> , ATCC 27853	22 - 28
<i>Escherichia coli</i> , ATCC 25922	27 - 33
<i>Staphylococcus aureus</i> , ATCC 25923	23 - 30

THERAPEUTIC INDICATIONS

Mono-therapy

SULPERAZON is indicated for the treatment of the following infections when caused by susceptible organisms:

Respiratory Tract Infections (Upper and Lower)
Urinary Tract Infections (Upper and Lower)
Peritonitis, Cholecystitis, Cholangitis, and Other Intra-abdominal Infections
Skin and Soft Tissue Infections

Combination Therapy

Because of the broad spectrum of activity of SULPERAZON, most infections can be treated adequately with this antibiotic alone. However, SULPERAZON may be used concomitantly with other antibiotics if such combinations are indicated. If an aminoglycoside is used (see section Incompatibilities, *Aminoglycosides*), renal function should be monitored during the course of therapy (see section POSOLOGY AND METHOD OF ADMINISTRATION, *Use in Renal Dysfunction*).

CONTRAINDICATIONS

SULPERAZON is contraindicated in patients with known hypersensitivity to any component of this product or to other drugs in the same class or in patients who have demonstrated severe hypersensitivity to beta-lactams (see section SPECIAL WARNINGS AND PRECAUTIONS FOR USE).

SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Hypersensitivity

Generic Name: Sulbactam Sodium/Cefoperazone Sodium
Trade Name: SULPERAZON
CDS Effective Date: October 14, 2022
Supersedes: March 28, 2019
Approved by BPOM: November 15, 2023

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam or cephalosporin therapy, including sulbactam/cefoperazone. These reactions are more apt to occur in individuals with a history of hypersensitivity reactions to multiple allergens.

Before therapy with sulbactam/cefoperazone is instituted, careful inquiry should be made to determine whether the patient has had previous hypersensitivity reactions to cephalosporins, penicillins or other drugs (see section CONTRAINDICATIONS). Antibiotics should be administered with caution to any patient who has demonstrated some form of allergy, particularly to drugs.

If an allergic reaction occurs, the drug should be discontinued and the appropriate therapy instituted.

Serious anaphylactic reactions require immediate emergency treatment with epinephrine. Oxygen, intravenous steroids, and airway management, including intubation, should be administered as indicated (see section UNDESIRABLE EFFECTS).

Severe and occasionally fatal skin reactions such as toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), and dermatitis exfoliative have been reported in patients on sulbactam/cefoperazone therapy. If a severe skin reaction occurs sulbactam/cefoperazone should be discontinued and appropriate therapy should be initiated (see section UNDESIRABLE EFFECTS).

Use in Hepatic Dysfunction

Cefoperazone is extensively excreted in bile. The serum half-life of cefoperazone is usually prolonged and urinary excretion of the drug increased in patients with hepatic diseases and/or biliary obstruction. Even with severe hepatic dysfunction, therapeutic concentrations of cefoperazone are obtained in bile and only a 2- to 4-fold increase in half-life is seen.

Dose modification may be necessary in cases of severe biliary obstruction, severe hepatic disease or in cases of renal dysfunction coexistent with either of those conditions.

In patients with hepatic dysfunction and concomitant renal impairment, cefoperazone serum concentrations should be monitored and dosage adjusted as necessary. In these cases dosage should not exceed 2 g/day of cefoperazone without close monitoring of serum concentrations.

General

Serious haemorrhage cases, including fatalities, have been reported with sulbactam/cefoperazone.

As with other antibiotics, Vitamin K deficiency resulting in coagulopathy has occurred in patients treated with sulbactam/cefoperazone. The mechanism is most probably related to the suppression of gut flora which normally synthesize this vitamin. Those at risk include patients with poor diet,

Generic Name: Sulbactam Sodium/Cefoperazone Sodium
Trade Name: SULPERAZON
CDS Effective Date: October 14, 2022
Supersedes: March 28, 2019
Approved by BPOM: November 15, 2023

malabsorption states (e.g., cystic fibrosis) and patients on prolonged intravenous alimentation regimens. Prothrombin time should be monitored in these patients, and patients receiving anticoagulant therapy, and exogenous vitamin K administered as indicated. Discontinue sulbactam/cefoperazone if there is persistent bleeding and no alternative explanations are identified.

As with other antibiotics, overgrowth of non-susceptible organisms may occur during prolonged use of SULPERAZON. Patients should be observed carefully during treatment. As with any potent systemic agent, it is advisable to check periodically for organ system dysfunction during extended therapy; this includes renal, hepatic, and hematopoietic systems. This is particularly important in neonates, especially when pre-mature, and other children.

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including sulbactam sodium/cefoperazone sodium, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C. difficile*.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

Use in Children

SULPERAZON has been effectively used in children. It has not been extensively studied in pre-mature infants or neonates. Therefore, in treating pre-mature children and neonates potential benefits and possible risks involved should be considered before instituting therapy (see section Preclinical Safety Data *Usage in Pediatrics*).

Cefoperazone does not displace bilirubin from plasma protein binding sites.

Interaction with Other Medicaments and Other Forms of Interaction

Alcohol

A reaction characterized by flushing, sweating, headache, and tachycardia has been reported when alcohol was ingested during and as late as the fifth day after cefoperazone administration. A similar reaction has been reported with certain other cephalosporins and patients should be cautioned concerning ingestion of alcoholic beverages in conjunction with administration of SULPERAZON. For patients requiring artificial feeding orally or parenterally, solutions containing ethanol should be avoided.

Generic Name: Sulbactam Sodium/Cefoperazone Sodium
Trade Name: SULPERAZON
CDS Effective Date: October 14, 2022
Supersedes: March 28, 2019
Approved by BPOM: November 15, 2023

Drug Laboratory Test Interactions

A false-positive reaction for glucose in the urine may occur with Benedict's or Fehling's solution.

Pregnancy and Lactation

Usage during Pregnancy

Reproduction studies have been performed in rats at doses up to 10 times the human dose and have revealed no evidence of impaired fertility and no teratological findings. Sulbactam and cefoperazone cross the placental barrier. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Usage in Nursing Mothers

Only small quantities of sulbactam and cefoperazone are excreted in human milk. Although both drugs pass poorly into breast milk of nursing mothers, caution should be exercised when SULPERAZON is administered to a nursing mother.

Effects on Ability to Drive and Use Machines

Clinical experience with sulbactam/cefoperazone indicates that is unlikely to impair a patient's ability to drive or use machines.

UNDESIRABLE EFFECTS

SULPERAZON is generally well tolerated. The majority of adverse events are of mild or moderate severity and are tolerated with continued treatment. The following ADRs were observed in clinical trials (comparative and non-comparative studies) and in the post-marketing.

All ADRs listed in the label are presented by MedDRA SOC and the ADRs are presented in the order of clinical importance.

ADRs by SOC and CIOMS frequency category listed in order of decreasing medical seriousness or clinical importance within each frequency category and SOC.				
System Organ Class	Very Common ≥1/10	Common ≥1/100 to <1/10	Uncommon ≥1/1000 to <1/100	Frequency Not Known (cannot be estimated from the available data)

Generic Name: Sulbactam Sodium/Cefoperazone Sodium
Trade Name: SULPERAZON
CDS Effective Date: October 14, 2022
Supersedes: March 28, 2019
Approved by BPOM: November 15, 2023

Blood and lymphatic system disorders	Neutropenia [†] , Leukopenia [†] , Coombs direct test positive [†] , Haemoglobin decreased [†] , Haematocrit decreased [†] , Thrombocytopenia [†]	Coagulopathy*, Eosinophilia [†]		Hypoprothrombinaemia*
Immune system disorders				Anaphylactic shock* [§] , Anaphylactic reaction* [§] , Anaphylactoid reaction [§] including shock*, Kounis syndrome*, ** Hypersensitivity* [§]
Nervous system disorders			Headache	
Vascular disorders				Haemorrhage* [§] Vasculitis*, Hypotension*
Gastrointestinal disorders		Diarrhoea, Nausea, Vomiting		Pseudomembranous colitis*
Hepatobiliary disorders	Alanine aminotransferase increased [†] , Aspartate aminotransferase increased [†] , Blood alkaline phosphatase increased [†]	Blood bilirubin increased [†]		Jaundice*
Skin and subcutaneous tissue disorders			Pruritus, Urticaria	Toxic epidermal necrolysis* [§] Stevens Johnson syndrome* [§] , Dermatitis exfoliative* [§] , Rash maculopapular*
Renal and urinary disorders				Haematuria*
General disorders and administration site conditions			Infusion site phlebitis, Injection site pain, Pyrexia, Chills	

Generic Name: Sulbactam Sodium/Cefoperazone Sodium
Trade Name: SULPERAZON
CDS Effective Date: October 14, 2022
Supersedes: March 28, 2019
Approved by BPOM: November 15, 2023

* ADR identified post-marketing
** Acute coronary syndrome associated with an allergic reaction.
† In the calculation for laboratory abnormality ADR frequencies, all available laboratory values, including those of subjects with baseline abnormalities, were included. This conservative approach was taken because the raw data did not allow distinction between the subset of subjects with baseline abnormalities who had treatment-emergent significant laboratory changes from those subjects with baseline abnormalities who did not have treatment-emergent significant laboratory changes.
For leucocytes, neutrophils, platelets, haemoglobin and haematocrit, only abnormalities are reported in studies. Increases and decreases are not differentiated.
§ Fatalities have been reported.

POSOLOGY AND METHOD OF ADMINISTRATION

Use in Adults

Daily dosage recommendations for SULPERAZON in adults are as follows:

Ratio	Sulperazon (g)	Sulbactam Activity (g)	Cefoperazone Activity (g)
1:1	2.0 - 4.0	1.0 - 2.0	1.0 - 2.0

Doses should be administered every 12 hours in equally divided doses.

In severe or refractory infections the daily dosage of SULPERAZON may be increased up to 8 g of the 1:1 (i.e., 4 g cefoperazone activity). Patients receiving the 1:1 ratio may require additional cefoperazone administered separately. Doses should be administered every 12 hours in equally divided doses.

The recommended maximum daily dosage of sulbactam is 4 g.

Use in Hepatic Dysfunction

See section SPECIAL WARNINGS AND PRECAUTIONS FOR USE.

Use in Renal Dysfunction

Dosage regimens of SULPERAZON should be adjusted in patients with marked decrease in renal function (creatinine clearance of less than 30 ml/min) to compensate for the reduced clearance of sulbactam. Patients with creatinine clearances between 15 and 30 ml/min should receive a maximum of 1 g of sulbactam administered every 12 hours (maximum daily dosage of 2 g sulbactam), while patients with creatinine clearances of less than 15 ml/min should receive a

Generic Name: Sulbactam Sodium/Cefoperazone Sodium
Trade Name: SULPERAZON
CDS Effective Date: October 14, 2022
Supersedes: March 28, 2019
Approved by BPOM: November 15, 2023

maximum of 500 mg of sulbactam every 12 hours (maximum daily dosage of 1 g sulbactam). In severe infections it may be necessary to administer additional cefoperazone.

The pharmacokinetic profile of sulbactam is significantly altered by haemodialysis. The serum half-life of cefoperazone is reduced slightly during haemodialysis. Thus, dosing should be scheduled to follow a dialysis period.

Use in Elderly

See section Pharmacokinetic Properties.

Use in Children

Daily dosage recommendations for SULPERAZON in children are as follows:

Ratio	Sulperazon mg/kg/day	Sulbactam Activity mg/kg/day	Cefoperazone Activity mg/kg/day
1:1	40 - 80	20 - 40	20 - 40

Doses should be administered every 6 to 12 hours in equally divided doses.

In serious or refractory infections, these dosages may be increased up to 160 mg/kg/day of the 1:1 ratio. Doses should be administered in two to four equally divided doses (see section SPECIAL WARNINGS AND PRECAUTIONS FOR USE, *Use in Children* and section Pre-clinical Safety Data *Usage in Pediatrics*).

Use in Neonates

For neonates in the first week of life, the drug should be given every 12 hours. The maximum daily dosage of sulbactam in pediatrics should not exceed 80 mg/kg/day. For doses of SULPERAZON requiring more than 80 mg/kg/day cefoperazone activity, additional cefoperazone should be administered separately (see section SPECIAL WARNINGS AND PRECAUTIONS FOR USE, *Use in Children*).

Intravenous Administration

For intermittent infusion, each vial of SULPERAZON should be reconstituted with the appropriate amount (see section Instructions for Use/Handling, *Reconstitution*) of 5% dextrose in Water, 0.9% Sodium Chloride Injection or Sterile Water for Injection and then diluted to 20 ml with the same solution followed by administration over 15 to 60 minutes.

Generic Name: Sulbactam Sodium/Cefoperazone Sodium
Trade Name: SULPERAZON
CDS Effective Date: October 14, 2022
Supersedes: March 28, 2019
Approved by BPOM: November 15, 2023

Lactated Ringer's Solution is a suitable vehicle for intravenous infusion, however, not for initial reconstitution (see section Incompatibilities, *Lactated Ringer's Solution* and section Instructions for Use/Handling, *Lactated Ringer's Solution*).

For intravenous injection, each vial should be reconstituted as above and administered over a minimum of 3 minutes.

Intramuscular Administration

Lidocaine HCl 2% is a suitable vehicle for intramuscular administration, however, not for initial reconstitutions (see section Incompatibilities, *Lidocaine* and section Instructions for Use/Handling, *Lidocaine*).

Instructions for Use/Handling

Reconstitution

SULPERAZON is available in 1.0 g and 2.0 g strength vials.

<u>Total Dosage (g)</u>	<u>Equivalent Dosage of sulb. + cefoperazone (g)</u>	<u>Volume of Diluent</u>	<u>Maximum Final Conc. (mg/ml)</u>
1.0	0.5 + 0.5	3.4	125 + 125
2.0	1.0 + 1.0	6.7	125 + 125

SULPERAZON has been shown to be compatible with these diluents: water for injection, 5% dextrose, normal saline, 5% dextrose in 0.225% saline, and 5% dextrose in normal saline. Cefoperazone is compatible at concentrations ranging from 10-250 mg/ml of diluent. Sulbactam is compatible at concentrations ranging from 5-125 mg/ml of diluent.

Lactated Ringer's Solution

Sterile Water for Injection should be used for reconstitution (see section Incompatibilities *Lactated Ringer's Solution*). A two step dilution is required using Sterile Water for Injection (shown in table above) further diluted with Lactated Ringer's Solution to a sulbactam concentration of 5 mg/ml (use 2 ml initial dilution in 50 ml or 4 ml initial dilution in 100 ml Lactated Ringer's Solution).

Lidocaine

Sterile Water for Injection should be used for reconstitution (see section Incompatibilities, *Lidocaine*). For a concentration of cefoperazone of 250 mg/ml or larger, a two step dilution is required using Sterile Water for Injection (shown in table above) further diluted with 2% lidocaine

Generic Name: Sulbactam Sodium/Cefoperazone Sodium
Trade Name: SULPERAZON
CDS Effective Date: October 14, 2022
Supersedes: March 28, 2019
Approved by BPOM: November 15, 2023

to yield solutions containing up to 250 mg cefoperazone and 125 mg sulbactam per ml in approximately a 0.5% lidocaine HCl solution.

Incompatibilities

Aminoglycosides

Solutions of SULPERAZON and aminoglycosides should not be directly mixed, since there is a physical incompatibility between them. If combination therapy with SULPERAZON and an aminoglycoside is contemplated (see section THERAPEUTIC INDICATIONS, *Combination Therapy*) this can be accomplished by sequential intermittent intravenous infusion provided that separate secondary intravenous tubing is used, and that the primary intravenous tubing is adequately irrigated with an approved diluent between doses. It is also suggested that doses of SULPERAZON be administered throughout the day at times as far removed from administration of the aminoglycoside as possible.

Lactated Ringer's Solution

Initial reconstitution with Lactated Ringer's Solution should be avoided since these mixtures have been shown to be incompatible. However, a two step dilution process involving initial reconstitution in water for injection will result in a compatible mixture when further diluted with Lactated Ringer's Solution (see section Instructions for Use/Handling, *Lactated Ringer's Solution*).

Lidocaine

Initial reconstitution with 2% lidocaine HCl solution should be avoided since these mixtures have been shown to be incompatible. However, a two step dilution process involving initial reconstitution in water for injection will result in a compatible mixture when further diluted with 2% lidocaine HCl solution (see section Instruction for Use/Handling, *Lidocaine*).

OVERDOSE

Limited information is available on the acute toxicity of cefoperazone sodium and sulbactam sodium in humans. Overdosage of the drug would be expected to produce manifestations that are principally extensions of the adverse reactions reported with the drug. The fact that high CSF concentrations of β -lactam antibiotics may cause neurologic effects, including seizures, should be considered. Because cefoperazone and sulbactam are both removed from the circulation by haemodialysis, these procedures may enhance elimination of the drug from the body if overdosage occurs in patients with impaired renal function.

Generic Name: Sulbactam Sodium/Cefoperazone Sodium
Trade Name: SULPERAZON
CDS Effective Date: October 14, 2022
Supersedes: March 28, 2019
Approved by BPOM: November 15, 2023

SUPPLY

Box, contains of 1 vial of SULPERAZON 1 g; Reg. No. DKI0284800844A1

HARUS DENGAN RESEP DOKTER PRESCRIPTION ONLY

Store below 25°C in a dry place.

SULPERAZON Injection

Manufactured by:
Haupt Pharma Latina S.r.l., Latina, Italy

Imported and packed by:
PT Pfizer Indonesia
Jakarta, Indonesia

Water for Injection

Manufactured by:
PT Phapros Indonesia
for PT Pfizer Indonesia